Sanofi (SNY) Free Cash Flow (2009 - 2026)
Sanofi (SNY) posted Free Cash Flow of $3.4 billion for Q2 2026, up 74.62% sequentially from $2.0 billion in Q1 2026, and up 107.9% YoY from $1.7 billion in Q2 2025.
Sanofi (SNY) Free Cash Flow (2009 - 2026) Analysis & Trends
Sanofi has reported Free Cash Flow for 9 years, with the latest figure at $3.4 billion in Q2 2026.
- Quarterly Free Cash Flow rose 107.9% year-over-year to $3.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $25.2 billion (up 12.2% YoY) and the FY2025 annual result came in at $8.4 billion, up 33.47% from the prior year.
- Free Cash Flow climbed to $3.4 billion in Q2 2026 per SNY's latest filing, from $2.0 billion in the prior quarter.
- Over five years, Free Cash Flow peaked at $12.0 billion in Q4 2023 and troughed at $95.6 million in Q1 2024.
- A 5-year average of $5.1 billion and a median of $3.2 billion in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow slumped 96.76% in 2024, then jumped 2202.93% in 2025.
- Over 5 years, Free Cash Flow stood at $11.2 billion in 2022, then increased by 6.9% to $12.0 billion in 2023, then fell by 12.22% to $10.5 billion in 2024, then advanced by 6.97% to $11.2 billion in 2025, then plunged by 69.38% to $3.4 billion in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered $3.4 billion, $2.0 billion, and $11.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 7.30 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.11 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 4.48 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.56 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -1.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 3.49 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.43 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 302.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 440.07 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 2.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.44 Bn |
| Jun 30, 2026 | 3.44 Bn |
| Mar 31, 2026 | 1.97 Bn |
| Mar 31, 2026 | 1.97 Bn |
| Dec 31, 2025 | 11.24 Bn |
| Dec 31, 2025 | 11.24 Bn |
| Sep 30, 2025 | 8.54 Bn |
| Sep 30, 2025 | 8.54 Bn |
| Jun 30, 2025 | 1.65 Bn |
| Jun 30, 2025 | 1.65 Bn |
| Mar 31, 2025 | 2.20 Bn |
| Mar 31, 2025 | 2.20 Bn |
| Dec 31, 2024 | 10.51 Bn |
| Dec 31, 2024 | 10.51 Bn |
| Sep 30, 2024 | 8.09 Bn |
| Sep 30, 2024 | 8.09 Bn |
| Jun 30, 2024 | 1.44 Bn |
| Jun 30, 2024 | 1.44 Bn |
| Mar 31, 2024 | 95.60 Mn |
| Mar 31, 2024 | 95.60 Mn |